REGN - Company ID 0000872589
REGENERON PHARMACEUTICALS, INC. trades as REGN and has a market capitalization of $56.80 B, making it the #295 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $14.34B, up 1.0% from the prior year and net income of $4.50B. This page tracks REGENERON PHARMACEUTICALS, INC. through 985 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-06-10
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years REGENERON PHARMACEUTICALS, INC.'s revenue grew from $4.86B to $14.34B, a compound annual growth rate of 12.8%. Net profit margin expanded from 18.4% to 31.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Institutional holdings | 13F-HR | 2026-05-08 |
| Insider trade | 4 | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-29 |
| Major company event | 8-K | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
| Annual report to shareholders | ARS | 2026-04-24 |
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak | Regeneron Pharmaceuticals Inc.
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss | Regeneron Pharmaceuticals Inc.
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis | Regeneron Pharmaceuticals Inc.
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas | Regeneron Pharmaceuticals Inc.
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma | Regeneron Pharmaceuticals Inc.
The largest companies sharing REGENERON PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
REGENERON PHARMACEUTICALS, INC. (REGN) has a market capitalization of $56.80 B as of 2026-06-10, ranking #295 among US-listed companies.
REGENERON PHARMACEUTICALS, INC. reported revenue of $14.34B for fiscal year 2025, an increase of 1.0% year over year.
Yes. REGENERON PHARMACEUTICALS, INC. reported net income of $4.50B in its latest fiscal year.